SPOTLIGHT: ImClone pushes new indication

Following the successful conclusion of trials into Erbitux for head and neck cancer, ImClone says it will seek expanded use of the cancer drug in the third quarter. Erbitux is currently indicated for colorectal cancer. Story

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.